**Supplementary Table 2. The raw data extracted from each study for CHB patients with positive HBeAg**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Study** | **year** | **r** | **n** | **ALT** | **HBV DNA** | **inflammation** |
| Schwarz KB | 2019 | -0.07 | 274 | Range:42 (13-2067) U/L | Range:8.23(3.53-ALQ) log10 IU/mL | Most active |
| Demirören K | 2015 | -0.322 | 56 | 86±44U/L | 8.1±1.8copy/mL, log10 | active |
| Elbir P | 2014 | 0.027 | 79 | NA | 239.9 (254.9) x 106 copies/ml | NA |
| Larsson SB | 2014 | 0.104 | 36 | Range:1.48 (0.24–8.13) ULN | Range:8.56 (3.76–10.10) log copies/ml | most active |
| Mao QG | 2010 | 0.07 | 474 | Range:250 (16-1908) U/L | Range:250 (16-1908) (log copies/mL) | Most active |
| Shao J | 2007 | 0.018 | 178 | 151 ± 82 U/L | 9.8 ± 1.3Log 10copies/mL | active |
| Keun ChunY | 2000 | 0.0334 | 178 | NA | molecules/mL median,109; mini,103; max, ,1013 | Most active |
| Total |  |  | 1275 |  |  |  |

CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase.